Which has higher earnings and valuation, NUVL or VERA?

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is NUVL or VERA more profitable?

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Vera Therapeutics N/A -74.86% -60.18%

Does the media favor NUVL or VERA?

In the previous week, Nuvalent and Nuvalent both had 3 articles in the media. Nuvalent's average media sentiment score of 1.12 beat Vera Therapeutics' score of 0.87 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or KRYS?

In the previous week, Krystal Biotech had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Krystal Biotech and 3 mentions for Vera Therapeutics. Krystal Biotech's average media sentiment score of 1.18 beat Vera Therapeutics' score of 0.87 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or VERA?

Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 104.19%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has stronger valuation & earnings, RGC or VERA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is RGC or VERA more profitable?

Regencell Bioscience's return on equity of 0.00% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Vera Therapeutics N/A -74.86% -60.18%

Does the media prefer RGC or VERA?

In the previous week, Regencell Bioscience had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 22 mentions for Regencell Bioscience and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat Regencell Bioscience's score of 0.03 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or CYTK?

In the previous week, Cytokinetics had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 3 mentions for Vera Therapeutics. Cytokinetics' average media sentiment score of 0.97 beat Vera Therapeutics' score of 0.87 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, VERA or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is VERA or ABVX more profitable?

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -74.86% -60.18% Abivax N/A -99.02% -70.26%

Does the media refer more to VERA or ABVX?

In the previous week, Abivax had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Abivax and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat Abivax's score of 0.28 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vera Therapeutics (VERA) Competitors

$38.20 -0.23 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$38.17 -0.03 (-0.07%)

As of 08:00 PM Eastern

Compare

VERA vs. NUVL, KRYS, RGC, CYTK, and ABVX

Should you buy Vera Therapeutics stock or one of its competitors? MarketBeat compares Vera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vera Therapeutics include Nuvalent (NUVL), Krystal Biotech (KRYS), Regencell Bioscience (RGC), Cytokinetics (CYTK), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Vera Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Nuvalent and Nuvalent both had 3 articles in the media. Nuvalent's average media sentiment score of 1.12 beat Vera Therapeutics' score of 0.87 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Nuvalent presently has a consensus target price of $131.15, suggesting a potential upside of 6.25%. Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 104.19%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Vera Therapeutics	N/A	-74.86%	-60.18%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vera Therapeutics beats Nuvalent on 8 of the 12 factors compared between the two stocks.

How does Vera Therapeutics compare to Krystal Biotech?

Vera Therapeutics (NASDAQ:VERA) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Vera Therapeutics presently has a consensus price target of $78.00, suggesting a potential upside of 104.19%. Krystal Biotech has a consensus price target of $340.56, suggesting a potential upside of 0.10%. Given Vera Therapeutics' higher possible upside, equities analysts plainly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Krystal Biotech had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Krystal Biotech and 3 mentions for Vera Therapeutics. Krystal Biotech's average media sentiment score of 1.18 beat Vera Therapeutics' score of 0.87 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48

Vera Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Krystal Biotech	53.92%	19.25%	17.62%

Summary

Krystal Biotech beats Vera Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Regencell Bioscience had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 22 mentions for Regencell Bioscience and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat Regencell Bioscience's score of 0.03 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 104.19%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Regencell Bioscience's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Vera Therapeutics	N/A	-74.86%	-60.18%

Summary

Vera Therapeutics beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Vera Therapeutics compare to Cytokinetics?

Vera Therapeutics (NASDAQ:VERA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vera Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Vera Therapeutics currently has a consensus price target of $78.00, indicating a potential upside of 104.19%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 24.11%. Given Vera Therapeutics' higher probable upside, research analysts clearly believe Vera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 3 mentions for Vera Therapeutics. Cytokinetics' average media sentiment score of 0.97 beat Vera Therapeutics' score of 0.87 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Cytokinetics	$105.82M	94.09	-$784.96M	-$6.84	N/A

Summary

Vera Therapeutics and Cytokinetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Abivax?

Vera Therapeutics (NASDAQ:VERA) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vera Therapeutics presently has a consensus price target of $78.00, suggesting a potential upside of 104.19%. Abivax has a consensus price target of $130.08, suggesting a potential upside of 32.15%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Abivax had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Abivax and 3 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat Abivax's score of 0.28 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Abivax	N/A	-99.02%	-70.26%

Vera Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Vera Therapeutics beats Abivax on 10 of the 13 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.76B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-6.90	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	4.50	8.29	10.79	6.50
Net Income	-$299.61M	$23.85M	$3.56B	$336.88M
7 Day Performance	13.45%	5.21%	1.67%	-0.22%
1 Month Performance	12.22%	2.19%	0.43%	0.77%
1 Year Performance	76.44%	60.99%	32.84%	31.57%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.3723 of 5 stars	$38.20 -0.6%	$78.00 +104.2%	+84.2%	$2.76B	N/A	N/A	40	Gap Down
NUVL Nuvalent	1.8203 of 5 stars	$123.35 +0.1%	$131.15 +6.3%	+64.6%	$9.74B	N/A	N/A	40	Positive News
KRYS Krystal Biotech	2.4903 of 5 stars	$324.75 +2.1%	$324.11 -0.2%	+159.3%	$9.37B	$389.13M	43.42	210	Positive News Analyst Downgrade
RGC Regencell Bioscience	0.4001 of 5 stars	$17.09 -9.2%	N/A	-72.3%	$9.31B	N/A	N/A	10	Trending News
CYTK Cytokinetics	3.5363 of 5 stars	$71.38 +1.8%	$99.30 +39.1%	+144.1%	$8.73B	$88.04M	N/A	250	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. NUVL, KRYS, RGC, CYTK, and ABVX

How does Vera Therapeutics compare to Nuvalent?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Summary

How does Vera Therapeutics compare to Regencell Bioscience?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Summary

How does Vera Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. NUVL, KRYS, RGC, CYTK, and ABVX

How does Vera Therapeutics compare to Nuvalent?

Does the media favor NUVL or VERA?

Which has more risk & volatility, NUVL or VERA?

Do analysts recommend NUVL or VERA?

Which has higher earnings and valuation, NUVL or VERA?

Is NUVL or VERA more profitable?

Do institutionals and insiders hold more shares of NUVL or VERA?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Do analysts recommend VERA or KRYS?

Does the media refer more to VERA or KRYS?

Do institutionals & insiders have more ownership in VERA or KRYS?

Which has higher earnings and valuation, VERA or KRYS?

Which has more risk and volatility, VERA or KRYS?

Is VERA or KRYS more profitable?

Summary

How does Vera Therapeutics compare to Regencell Bioscience?

Does the media prefer RGC or VERA?

Which has more volatility & risk, RGC or VERA?

Do analysts rate RGC or VERA?

Which has stronger valuation & earnings, RGC or VERA?

Do insiders & institutionals hold more shares of RGC or VERA?

Is RGC or VERA more profitable?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Do institutionals & insiders believe in VERA or CYTK?

Which has more volatility and risk, VERA or CYTK?

Do analysts rate VERA or CYTK?

Is VERA or CYTK more profitable?

Does the media refer more to VERA or CYTK?

Which has stronger earnings and valuation, VERA or CYTK?

Summary

How does Vera Therapeutics compare to Abivax?

Do insiders & institutionals have more ownership in VERA or ABVX?

Do analysts recommend VERA or ABVX?

Does the media refer more to VERA or ABVX?

Is VERA or ABVX more profitable?

Which has more risk & volatility, VERA or ABVX?

Which has higher earnings & valuation, VERA or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools